Clinical trial · Observational
Endocan Levels at Polycystic Ovary Syndrome and Periodontal Inflammation
The Levels of Interleukin-6 and Endocan at Individuals With Polycystic Ovary Syndrome and Periodontal Inflammation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Periodontal diseases are chronic inflammatory disease occurred by the interaction between pathogenic microorganism and the host defense. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease associated with increased risk of cardiovascular events. Endocan is a proteoglycan secreted mainly by endothelial cells under the control of inflammatory cytokines. Periodontal diseases, including gingivitis, are common chronic infectious diseases caused by predominantly pathogenic microorganisms that colonize the subgingival area and cause local and systemic elevations of proinflammatory cytokines such as Interleukin-6 (IL-6). Several lines of evidence established the association between periodontal and systemic diseases, including metabolic syndrome, diabetes, and cardiovascular disease. Because of the fact that both periodontal disease and PCOS are associated with systemic inflammation and insulin resistance, these two disorders may be linked through a common pathophysiologic pathway. A number of studies have indicated a possible relationship between PCOS and periodontal inflammation. Despite common risk factors, including oxidative stress, the relationship between chronic periodontitis (CP) and PCOS remains unclear. The aims of the study were to determine serum and saliva Endocan and IL-6 levels and to evaluate the correlation between these two biomarker in women with periodontal disease and PCOS.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cytokines | — | UNRESOLVED | — |
| Inflammation Gum | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collection of Serum and Saliva Samples | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Group 1
- description
- PCOS participants with periodontitis
- interventionNames
- Diagnostic Test: Collection of Serum and Saliva Samples
- label
- Group 2
- description
- PCOS participants with periodontally healthy
- interventionNames
- Diagnostic Test: Collection of Serum and Saliva Samples
- label
- Group 3
- description
- systemically healthy participants with periodontitis
- interventionNames
- Diagnostic Test: Collection of Serum and Saliva Samples
- label
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed PCOS patients * Never smokers * Had no history of systemic disease * BMI\<25 kg/m2 * Participants had ≥20 teeth present. Exclusion Criteria: * Pregnancy * Lactation * Hemoglobin A1c (HbA1c) ≥ 6.5% * 2-h oral glucose tolerance test (OGTT-2h) ≥200 * Cushing syndrome, non-classic congenital adrenal hyperplasia, hyperprolactinemia, thyroid dysfunction, and androgen-secreting tumors * Using antibiotics and antiinflammatory within the past 6 months * Periodontal treatment within the past 6 months
References
Publications (0)
Data not yet available